Department of Cardiology Clinical Sciences Lund UniversitySkåne University Hospital Lund Sweden.
J Am Heart Assoc. 2021 Oct 19;10(20):e020974. doi: 10.1161/JAHA.121.020974. Epub 2021 Oct 6.
Background The Predicting Bleeding Complications in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy (PRECISE-DAPT) score has been shown to predict out-of-hospital major bleeding after myocardial infarction treated with percutaneous coronary intervention and dual antiplatelet therapy (DAPT). However, large validation studies have been scarce and the discriminative ability for patients with a preexisting bleeding risk factor (elderly, underweight, women, anemia, kidney dysfunction, or cancer) in a real-world setting is unknown. Methods and Results Patients undergoing percutaneous coronary intervention for myocardial infarction between 2008 and 2017 were included from the SWEDEHEART (Swedish Web System for Enhancement of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies) registry (n=66 295). The predictive value of the PRECISE-DAPT score for rehospitalization with major bleeding during dual antiplatelet therapy was evaluated using receiver operating characteristic analyses. A high PRECISE-DAPT score (≥25; n=13 894) was associated with increased risk of major bleeding (3.9% versus 1.8%; hazard ratio [HR], 2.2; 95% CI, 2.0-2.5; <0.001) compared with a non-high score (<25; n=52 401). The score demonstrated a c-statistic of 0.64 (95% CI, 0.63-0.66). The discriminative ability of the score to further stratify bleeding risk in patients with preexisting bleeding risk factors was poor, especially in patients who are elderly (c-statistic=0.57; 95% CI, 0.55-0.60) or underweight (c-statistic=0.56; 95% CI, 0.51-0.61), for whom a non-high PRECISE-DAPT score was associated with similar bleeding risk as a high PRECISE-DAPT score in the general myocardial infarction population. Conclusions In this nationwide population-based study, the PRECISE-DAPT score performed moderately in the general myocardial infarction population and poorly in patients with preexisting bleeding risk factors, where its usefulness seems limited.
PRECISE-DAPT 评分已被证明可预测接受经皮冠状动脉介入治疗和双联抗血小板治疗(DAPT)后心肌梗死患者的院外大出血。然而,大型验证研究相对较少,对于存在预先存在的出血风险因素(老年人、体重不足、女性、贫血、肾功能不全或癌症)的患者,该评分的区分能力尚不清楚。
本研究纳入了 2008 年至 2017 年期间因心肌梗死接受经皮冠状动脉介入治疗的 SWEDEHEART(瑞典心脏病基于推荐治疗的网络系统评估)注册登记研究患者(n=66295)。采用受试者工作特征曲线评估 PRECISE-DAPT 评分对双联抗血小板治疗期间因大出血再住院的预测价值。高 PRECISE-DAPT 评分(≥25;n=13894)与大出血风险增加相关(3.9%比 1.8%;风险比[HR],2.2;95%CI,2.0-2.5;<0.001),而低评分(<25;n=52401)则不然。该评分的 C 统计量为 0.64(95%CI,0.63-0.66)。该评分对预先存在出血风险因素的患者进一步分层出血风险的区分能力较差,尤其是在老年人(C 统计量=0.57;95%CI,0.55-0.60)或体重不足的患者中(C 统计量=0.56;95%CI,0.51-0.61),对于这些患者,非高 PRECISE-DAPT 评分与一般心肌梗死人群中高 PRECISE-DAPT 评分相关的出血风险相似。
在这项全国性基于人群的研究中,PRECISE-DAPT 评分在一般心肌梗死人群中的表现中等,在预先存在出血风险因素的患者中表现不佳,其用途似乎有限。